Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) – Equities research analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for shares of Adlai Nortye in a report issued on Monday, June 2nd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($1.08) for the year, down from their prior forecast of ($0.92). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Adlai Nortye’s FY2026 earnings at ($1.08) EPS.
Adlai Nortye Stock Up 3.7%
ANL opened at $1.70 on Thursday. The stock has a 50-day moving average price of $1.90 and a 200-day moving average price of $2.12. Adlai Nortye has a 1 year low of $1.10 and a 1 year high of $6.41.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
- Five stocks we like better than Adlai Nortye
- What is the Euro STOXX 50 Index?
- Intuit’s AI Boom: Stock Soaring, But Should Investors Hit Pause?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Top Dividend Plays With Strong Analyst Ratings
- How to Read Stock Charts for Beginners
- Robinhood Stock Keeps Giving Investors Reasons To Buy
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
